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 Abstract  
Objective-The drug warfarin blocks carboxylation of vitamin K dependent proteins and acts as 
an anticoagulant and an accelerant of vascular calcification. The calcification inhibitor matrix Gla 
protein (MGP), produced by vascular smooth muscle cells (VSMCs), is a key target of warfarin 
action in promoting calcification, however it remains unclear whether proteins in the coagulation 
cascade also play a role in calcification.  
Approach and Results-Vascular calcification is initiated by exosomes and proteomic analysis 
revealed that VSMC exosomes are loaded with Gla-containing coagulation factors; IX and X, 
prothrombin (PT) and proteins C and S. Tracing of Alexa488-labeled PT showed that exosome 
loading occurs by direct binding to externalized phosphatidylserine (PS) on the exosomal 
surface and by endocytosis and recycling via late endosomes/multivesicular bodies (LE/MVB). 
Notably, the PT Gla domain and a synthetic Gla-domain peptide inhibited exosome-mediated 
VSMC calcification by preventing nucleation site formation on the exosomal surface. PT was 
deposited in the calcified vasculature and there was a negative correlation between vascular 
calcification and the levels of circulating PT. In addition, we found that VSMC exosomes 
induced thrombogenesis in a tissue factor (TF)- and PS-dependent manner.  
Conclusions- Gamma carboxlyated coagulation proteins are potent inhibitors of vascular 
calcification suggesting warfarin action on these factors also contributes to accelerated 
calcification in patients receiving this drug. VSMC exosomes link calcification and coagulation 
acting as novel activators of the extrinsic coagulation pathway and inducers of calcification in 
the absence of Gla-containing inhibitors.  
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Graphic Abstract 
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Abbreviations 
EV, extracellular vesicles  
F1, prothrombin fragment 1 
F1.2, prothrombin fragment 1+2 
Gla, Carboxyglutamic acid 
LE/MVB, late endosomes/multivesicular bodies 
MGP, matrix Gla protein 
PIVKA-II, protein induced by vitamin K absence or antagonism II 
Pre2, prethrombin-2 (Pre-2)  
PS, phosphatidylserine  
PT, prothrombin 
TF, tissue factor  
VSMCs, vascular smooth muscle cells (VSMCs),  
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Introduction 
Vascular calcification contributes to increased cardiovascular morbidity and mortality in 
ageing, atherosclerosis, diabetes mellitus and chronic kidney failure1, 2. It occurs in the medial 
and intimal layers of arteries and is driven by vascular smooth muscle cells (VSMCs) which can 
undergo osteo-chondrogenic differentiation and secrete calcifying exosomes or apoptotic bodies 
that initiate deposition of calcium (Ca) phosphate (P) crystals3-5.  
Under physiological conditions VSMCs are protected from calcification by expression of 
inhibitors including the vitamin K-dependent proteins; matrix Gla protein (MGP), bone Gla 
protein (BGP; osteocalcin), Gla rich protein (GRP) and growth arrest-specific gene-6 protein 
(Gas 6)6-9. These proteins all contain specific glutamate residues (Glu) necessary for their 
function that are carboxylated in a vitamin K-dependent manner. Increased accumulation of 
uncarboxylated, inactive forms of MGP, GRP and BGP have been observed in the calcified 
vasculature or the circulation of patients with vascular calcification stressing the importance of 
adequate vitamin K-status in the inhibition of calcification8, 10-12. 
It is still unknown how calcification is inhibited by vitamin K-dependent proteins. Reduced 
Gas6 carboxylation results in inhibition of Axl-dependent anti-apoptotic pathways and 
subsequent VSMC apoptosis and calcification9, 13. MGP has been implicated in BMP-2 binding 
and inhibition of BMP2-dependent osteogenic signalling14. MGP has also been detected in 
VSMC exosomes where it inhibits Ca/P precipitation although the precise mechanisms by which 
the Gla domain inhibits the nucleation of Ca salts remain unclear15, 16. Interestingly, VSMCs 
internalise liver derived fetuin-A from the circulation and load it into exosomes where it acts as a 
potent inhibitor of calcification. Thus, both locally expressed as well as serum-derived proteins 
are involved in the prevention of exosome-mediated VSMC calcification5.  
Circulating vitamin K-dependent coagulation factors including prothrombin (PT) and 
factors VII, IX and X and proteins C and S also harbour Gla residues which mediate Ca-
dependent protein binding to negatively charged phospholipids, such as PS 17-21. Activation of 
coagulation in the vasculature has been linked to PS-exposing extracellular vesicles (EVs) shed 
by apoptotic macrophages, endothelial cells, erythrocytes and VSMCs17, 22 23, 24. In particular, 
the coagulation cascade is triggered by VSMC EVs bearing tissue factor (TF) that can activate 
Factor VII with subsequent activation of the prothrombinase complex (consisting of Factor Va, 
Factor Xa and calcium) to catalyze PT conversion to thrombin17, 22, 25-28. Anticoagulation therapy 
with warfarin causes elevation of circulating levels of liver-derived uncarboxylated PT (PIVKA-II) 
and results in the inhibition of thrombogenesis29. Besides its effect on vitamin K-dependent 
coagulation proteins, warfarin increases circulating levels of undercarboxylated MGP and BGP 
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and causes vascular calcification in rodent models and accelerates both valve and vascular 
calcification in man30-33.  However, despite the global use of anticoagulation therapies in clinical 
practice, the effects of warfarin on VSMC mediated calcification remain elusive.   
Here we report that circulating vitamin K-dependent coagulation proteins, PT in particular, 
can bind to the surface of VSMC exosomes via PS and can also be loaded into exosomes by 
cellular internalization and recycling via the late endosome/multivesicular body (LE/MVB) 
compartment. We identify PT as a novel circulating calcification inhibitor that also acts to induce 
thrombin generation in a TF- and PS-dependent manner on the surface of exosomes. Thus, 
anticoagulation therapy with warfarin may enhance vascular calcification via impaired 
carboxylation of vitamin K-dependent coagulation factors delivered to VSMC exosomes, which 
play a dual role in calcification and coagulation.    
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Material and methods 
Materials and Methods are available in the online-only Data Supplement. 
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Results 
Circulating Gla proteins are abundant in VSMC exosomes 
We previously demonstrated the recycling of the circulating serum protein, fetuin-A by 
VSMC exosomes.5 To determine whether other serum proteins are recycled in VSMC 
exosomes we interrogated a proteomic dataset of human VSMC-derived exosomes5, isolated 
under normal or calcifying conditions, for bovine proteins indicative of serum uptake. The most 
abundant bovine proteins in VSMC exosomes were albumin, fetuin-A and fibronectin (Table 1). 
Notably, circulating vitamin K-dependent coagulation proteins including factors II (PT), IX and X, 
and anticoagulation proteins C and S were also detected in VSMC-derived exosomes and their 
loading was increased under calcifying conditions (Table 1, Number of Assigned Spectra).           
We compared the primary structure of circulating vitamin K-dependent coagulation 
proteins and MGP7. The alignment of the Gla-domain sequences revealed a similarity, of over 
50% in the composition of the Gla-domain between vitamin K-dependent coagulation proteins 
(Supplementary Figs. S1A and S1B). Prominently, there were 4 conserved Glu-residues and 
one cysteine residue in all these proteins suggesting coagulation proteins may potentially 
modulate vascular calcification.  
 
Gla proteins differentially inhibit VSMC calcification in vitro 
VSMCs were treated with physiological doses of a number of Gla containing proteins to 
test their capacity to inhibit calcification in vitro (Fig. 1A). MGP is a potent local inhibitor of 
calcification however circulating MGP has no inhibitory properties in vivo34 and is only effective 
in vitro at doses above physiological levels35. As expected MGP1-53 (Supplementary Figs. S2A 
and C), osteopontin and osteocalcin had little effect on calcification when added exogenously to 
the media at circulating concentrations (Fig. 1A). In contrast PT, the most abundant circulating 
coagulation factor with physiological concentrations ∼1.4µM was able to potently inhibit 
calcification in a manner similar to fetuin A (Fig. 1A).  
PT expression was not observed in VSMCs either by western blotting or PCR 
(Supplementary Fig. S3A).  However, incubation of VSMCs with PT resulted in its accumulation 
in exosomes, apoptotic bodies and whole cell lysates (Fig. 1B) with exosomes also enriched 
with PT intermediate activation products, F1 and F1.2 (Fig. 1B). In agreement with our 
proteomic data, calcifying conditions increased the levels of PT and F1 both in exosomes and 
VSMCs (Fig. 1C).  
 
PT inhibits exosome-induced calcification and reduces VSMC apoptosis.  
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To test further the effects of PT on vascular calcification we treated VSMCs in elevated 
Ca/P conditions and assessed calcification by 45Ca incorporation and Alizarin red S staining 
(Figs. 2A and B). PT inhibited calcification in a dose-dependent manner at concentrations within 
the physiological range. The inhibitory effects of PT were more pronounced in Ca- rather than 
P-induced calcification (Supplementary Figs. S4A and S4B). Fetuin-A blocks calcification by 
binding to nascent Ca/P crystals preventing further growth and acting as a “mineral 
chaperone”.36, 37 Fetuin-A and PT inhibited VSMC calcification in a synergistic manner indicating 
that PT acts via different mechanisms (Fig. 2C) and in agreement with this fetuin-A but not PT 
completely prevented Ca/P precipitation in vitro (Fig. 2D).     
To study the effects of PT on exosome-initiated calcification, exosomes were isolated 
from VSMCs treated in the absence or presence of PT and their calcification potential was 
quantified ex vivo15. Exosomes isolated from Ca/P treated VSMCs displayed calcification (Fig. 
2E). Direct addition of PT to exosomes isolated from VSMCs incubated in Ca/P media 
significantly reduced exosome calcification (Fig. 2E), suggesting PT may inhibit calcification by 
binding to PS externalized on the exosome surface thus preventing nucleation site formation. 
However, inhibition of exosome calcification was also observed when VSMCs were treated with 
PT for 24h and then washed to remove PT from the media before exosome isolation 24h later, 
suggesting PT is also loaded into exosomes via the LE/MVB pathway.  
VSMC apoptosis also contributes to calcification and treatment of VSMCs with calcifying 
media resulted in apoptosis of approximately 20-25% of cells as assessed by TUNEL staining 
and time-lapse microscopy (Supplementary Figs. S4C and S4D). Addition of PT significantly 
reduced VSMC apoptosis induced by elevated Ca/P, but had no effect on apoptosis induced by 
serum withdrawal (data not shown), suggesting PT can prevent mineral overload induced 
apoptosis. 
 
PT is recycled in VSMC exosomes in a Ca-dependent manner.  
To test if PT can directly bind to VSMC exosomes we immobilised exosomes on latex 
beads, incubated with Alexa488-labelled PT and observed strong binding (Fig. 3A). The 
interaction of PT with PS is mediated by the N-terminal F1 domain harbouring Gla-residues20 
and, consistently, addition of annexin A5 or F1 blocked PT binding to exosomes (Fig. 3A). We 
also observed reciprocal competition for interactions with exosomal PS between PT and 
annexin A5 (Supplementary Fig. S3B).  
Addition of alexa488-labelled PT to VSMCs resulted in endocytosis of full-length PT in a 
Ca-dependent manner (Fig. 3B). To test whether PT endocytosis is mediated by high-affinity 
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binding to a cellular receptor or fluid-phase uptake38, we studied endocytosis of alexa488-
labelled PT in the presence of unlabeled PT. Notably, endocytosis of alexa488-labelled PT was 
inhibited by 5-fold molar excess of unlabelled PT, indicating that uptake is mediated by high 
affinity binding of PT to the cell surface potentially via Gla/PS binding (Fig. 3C).  Colocalization 
with EEA1 and CD63 showed that PT is endocytosed by VSMCs and delivered to early 
endosomal and LE/MVB compartments (Fig. 3D). Immunocytochemistry also confirmed that PT-
Alexa488 uptake was further stimulated by elevated Ca and inhibited by unlabelled PT (Fig. 3D). 
To distinguish PT which binds to exosomes in the cell media, and PT which is endocytosed and 
recycled in exosomes via LE/MVB we incubated VSMCs with PT for 16h (“pulse”) and then 
washed cells with acidic buffer (pH 2.5) to remove all cell-surface bound PT and continued 
incubation in media without PT (“chase”). Exosomes isolated from VSMCs incubated in the 
presence of PT in the media, were enriched with full-length protein and fragments, F1.2 and F1 
(Fig. 3E). In contrast, exosomes obtained after the chase treatment contained full length PT and 
its intermediate activation product with molecular weight ∼34kDa, most likely Pre2, an inactive 
α-thrombin precursor consisting of the catalytic domain. (Fig. 3E and Supplementary Fig. S1C). 
Thus, PT is loaded on, and in, exosomes by direct surface binding and cellular endocytosis.  
 
The Gla domain but not proteolytic activity is required for VSMC calcification inhibition by PT.  
To identify the domain of PT responsible for blocking calcification we tested different 
PT forms (Fig. 4A). F1 which contains 10 Gla residues was the most potent inhibitor, even more 
effective than full length PT. F2, which does not contain a Gla domain, and uncarboxylated 
(Glu)-PT were also able to inhibit calcification although to a much lesser extent, indicating that 
several domains contribute to PT effects on calcification. In contrast, thrombin had no effect on 
VSMC calcification (Fig. 4A). To confirm that catalytic activity is not required for the PT inhibitory 
effect, we showed that addition of the thrombin inhibitor hirudin did not abrogate PT inhibitory 
effects on VSMC calcification (Fig. 4B). Finally, to investigate whether other Gla-containing 
coagulation proteins identified in exosomes may also affect VSMC calcification, we used a Gla 
peptide representing the N-terminal region of protein S containing 11 Gla residues which forms 
a stable conformation due to its intramodular disulfide loop (Supplementary Figs. S2B and S2C). 
Addition of this Gla peptide completely abrogated VSMC calcification (Fig. 4B) confirming the 
utility of Gla residues in inhibiting calcification. 
 
PT accumulates at sites of calcification in vivo and is reduced in patients with vascular 
calcification. 
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To confirm a relationship between calcification and PT we analysed the distribution of PT 
in the calcified vasculature using an F1-specific antibody. Immunohistochemistry showed that 
low levels of PT were deposited in the healthy vessel wall while in calcified vessels PT was 
significantly present in both intimal and medial layers (Fig. 4C). Moreover, we observed overlap 
between the distribution of PT and fetuin-A, suggesting that PT is deposited in the vessel wall 
most likely via exosomes in a manner similar to fetuin-A5, 36.   
Fetuin-A levels are reduced in patients with vascular calcification, thus we tested 
whether there is also a correlation between vascular calcification and PT concentration. 
Vascular calcification of the iliac arteries was assessed by plain X-ray of the pelvis (Table 2). 
Patients with vascular calcification had lower levels of PT (p<0.01) when compared to patients 
without calcification. Univariate logistic regression confirmed this finding (p=0.012; hazard ratio 
0.971; 95% confidence interval 0.948–0.993) and after adjustment for age, gender, and 
diabetes mellitus the finding remained significant (p=0.004; hazard ratio 0.905; 95% confidence 
interval 0.845–0.969).  Addition of fetuin-A levels to the multivariable model did not change the 
results (data not shown). 
 
VSMC exosomes display TF and PS-dependent procoagulant activity. 
The accumulation of PT activation products, F1 and F1.2 in exosomes (Fig. 1B) 
suggested that exosomes may play a role in thrombin activation (Supplementary Fig. S1C) so 
we tested if VSMC exosomes contain TF and found it was enriched in exosomes but not 
apoptotic bodies (Fig. 5A).  The addition of VSMC exosomes to plasma potently stimulated 
thrombogenesis, which was abrogated in the presence of annexin A5 (Fig. 5B) confirming 
thrombogenic activity is via PS exposure. Once PT is activated, F1 and F1.2 bound to 
exosomes may prevent further activation of PT by blocking PS sites. Indeed, exosomes isolated 
from VSMCs pre-incubated with PT demonstrated reduced thrombogenic activity (Fig. 5C).  
Notably, no thrombin activation was observed in PT-deficient plasma upon addition of 
exosomes with bound PT (data not shown). PT binding to exosomes may prevent 
prothrombinase formation by blocking PS, so we tested if exosome-associated PT can be 
activated by a pre-activated prothrombinase complex.  First, we incubated PT and factors Va/Xa 
with exosomes isolated from VSMCs incubated in the absence of PT and analysed the 
supernatant and exosome-associated products by western blotting using antibodies specific for 
either F1 or catalytic domain (Fig. 5D). No PT was detected in the exosomes isolated from 
VSMCs incubated in PT-free conditions (Fig. 5D, lane 1). Upon addition of PT we observed 
soluble and exosome-associated full-length PT (Fig. 5D, lane 2). Addition of activated 
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prothrombinase (Va/Xa) along with PT resulted in the release of thrombin heavy chain (B chain) 
with molecular weight ∼31kDa in the supernatant phase (Fig 5D, lane 3). We also observed B 
chain and activation product F1 associated with exosomes  (Fig 5D, lane 3). Next, we analysed 
exosomes isolated from VSMCs treated in the presence of PT. Using anti-F1 antibodies we 
detected PT and PT intermediate activation products, F1, F1.2 associated with exosomes (Fig. 
5D, lane 4). Using an anti-catalytic domain antibody we detected PT and an intermediate 
activation product with molecular weight ∼34kDa (Fig. 5C, line 4), again most likely Pre2 as 
compared to the position of B chain (Fig 5D, lane 3). Addition of prothrombinase had no effect 
on exosome-associated PT and PT activation products (Fig. 5D, line 5), indicating that there is a 
pool of exosome-bound PT and PT intermediate activation products not available to 
prothrombinase. Thus, VSMC exosomes are thrombogenic however accumulation of PT and PT 
intermediate activation products reduces their pro-thrombogenic properties in a negative-
feedback loop.  
Altogether these data show that VSMC exosomes activate coagulation in a TF- and 
PS-dependent manner and accumulation of PT and PT activation products diminish both PS-
mediated pro-calcific and pro-coagulant exosomal activities in a negative-feedback manner (Fig. 
6).  
 
Discussion 
 
PT is loaded on VSMC exosomes and protects against calcification in a Gla-dependant 
manner.  
Vitamin K-antagonist treatment aimed at the prevention of thromboembolic complications 
causes accelerated vascular calcification in both animal models and patients32, 33 and this effect 
is thought to be associated with accumulation of uncarboxylated endogenously expressed Gla 
proteins such as MGP and GRP7, 8, 10, 30. In the present study we show for the first time that the 
Gla-residues in circulating coagulation factors, PT in particular, also contribute to inhibition of 
vascular calcification. As opposed to fetuin-A, a circulating calcification inhibitor which acts by 
direct binding to nascent growing calcium phosphate crystals to limit growth5, 37, PT  inhibits 
exosome-mediated  calcification via  a PS/Gla interaction, thus disrupting nucleation site 
formation. ‘Pulse-chase” experiments indicated that there are two mechanisms of PT loading 
into exosomes – direct binding to the exosomal membrane and calcium-dependent endocytosis 
and secretion via the LE/MVB/exosome pathway. The contribution of the latter pathway of PT 
loading into exosomes on calcification is currently unclear. This PT pool may be loaded inside 
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exosomes via unknown mechanisms described previously for fetuin-A5, 39 where it can shield 
luminal PS thus enhancing the overall protective effects against calcification. Interestingly, PT 
endocytosis and exosomal loading were stimulated by calcium, which is required for the PS/Gla 
interaction40 and elevated calcium conditions have been observed in atherosclerotic plaques41  
and in CKD patients suggesting that the internal loading pathway may be important under 
conditions of mineral imbalance. Accumulating evidence demonstrates the toxicity of crystalline 
Ca/P particles thus inhibition of crystal nucleation by PS/Gla interactions could also limit VSMC 
apoptosis42, 43. Interestingly, fragment F2 also displayed a modest protective effect indicating 
that the F2 kringle 2 domain could contribute to the regulation of VSMC viability in calcifying 
conditions by modulating cell signalling but this hypothesis is yet to be tested.  
Importantly, extensive calcification of elastic fibres is commonly observed in patients with 
pseudoxanthoma elasticum harbouring mutations in γ-glutamyl carboxylase which causes 
multiple coagulation factor deficiency44 providing further evidence that Gla-containing 
coagulation factors may regulate vascular calcification in vivo. PTs role in calcification is also 
supported independently by previous reports showing its presence in association with calcified 
kidney stones45. In this study we also detected PT in close association with calcified regions in 
human arteries where its distribution overlapped with fetuin-A deposits and the reduction of 
circulating PT levels negatively correlated with vascular calcification. These data mirror previous 
clinical data with fetuin-A showing reduced levels in dialysis patients who exhibit enhanced 
vascular calcification and mineral imbalance46. Interestingly, as opposed to MGP clinical data, 
the appearance of minute levels of under-carboxylated PT in the circulation (>2ng/ml which 
corresponds to ≈0.00003µmol/L) is not associated with vascular calcification47 as long as  the 
total circulating PT levels remain high (≈1.4µmol/L).  Although the mechanisms of fetuin-A and 
PT loss in the circulation in dialysis patients are yet to be investigated it is tempting to speculate 
that the major cause is the formation of fetuin-mineral complexes consisting of Ca/P and fetuin-
A initially identified in the serum of rats treated with bisphosphonates48. Formation of complexes 
between fetuin-A and nascent mineral nuclei into primary calciprotein complexes is thought to 
inhibit further mineral growth and may facilitate clearance from the blood48 and these complexes 
have been recently associated with coronary artery calcification scores and aortic aortic pulse 
wave velocity in CKD patients49, 50. However, the exact composition of these complexes remains 
elusive and PT and fetuin-A-loaded exosomes may contribute by providing the membrane 
surface to form the fetuin-A-mineral complex core at early phases of calciprotein complex 
formation.  In vivo these complexes are yet to be tested for the presence of PT and exosomal 
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markers such as CD63 or Tsg101 and it would also be interesting to test how warfarin treatment 
affects the composition of these complexes.  
 
VSMC exosomes are thrombogenic  
Recent studies suggest that thrombogenic activity in the atherosclerotic plaque is 
associated with EVs shed by apoptotic cells, especially VSMCs.17, 22, 25, 26 Although VSMC EV 
thrombogenic activity exceeds the potency of platelet-derived EVs, most likely due to the 
presence of TF and PS, the mechanisms of thrombogenic EV secretion by VSMCs remained 
unknown22. TF has recently been shown to be secreted in exosomes in various cell types and 
was detected in VSMCs in cytoplasmic MVB-like structures and in VSMC culture media in small 
particles of an unknown nature24, 51, 52. Here we report that apart from triggering calcification, PS 
externalized on VSMC exosomes, acts as a catalytic surface for thrombogenesis. Interestingly, 
aactivation of PT on apoptotic cells or synthetic PS/PC vesicles occurs via the initial cleavage of 
PT at R320 yielding meizothrombin, a potent activator of anti-coagulant pathways53, 54. In 
contrast, we detected Pre2 and F1.2 on VSMC exosomes indicating that activation of PT on 
VSMC exosomes occurs by the PT cleavage at R271 generating catalytically inactive Pre2 and 
F1.2 and Pre2 can be instantly cleaved at R320 generating procoagulant α-thrombin55. This 
specificity may be defined by specific membrane proteins, such as integrins as reported earlier 
for platelets56. Unexpectedly, we observed a pool of exosome-associated PT and Pre2 that was 
not available for activation by factor Xa and these exosomes displayed reduced thrombogenic 
activity. There are two possible explanations for this pool of PT that cannot be activated. Firstly, 
PT may be loaded inside the exosomal lumen as discussed above. Secondly, activation of PT 
by factor Xa, by cleavage of the R320 bond in particular, requires membrane binding of factor 
Xa suggesting sterical hindrance may prevent activation of PT and Pre228. 
In conclusion, PT is a novel circulating vascular calcification inhibitor acting via Gla/PS 
binding to exosomes.  Binding of PT to exosomes also activates coagulation pathways whilst 
gradual loading of exosomes with PT and PT activation products reduces both pro-calcification 
and pro-coagulant activities by Gla/PS interactions. Hence, vascular protection in patients at 
high risk for vascular calcification may be achieved by using direct oral anticoagulants instead of 
warfarin or by supplementation with small Gla peptides e.g. Gla peptide derivative from protein 
S. Modulation of exosome biogenesis pathways, such as SMPD3 which is activated in vascular 
pathologies57, 58 may also provide alternative therapeutic approaches to reduce plaque 
thrombogenicity causing late stage thrombotic events in patients after myocardial infarction or 
coronary artery stenting59.  
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Highlights. 
 
1. Circulating Gla proteins are abundant in VSMC exosomes. 
2. PT is a novel circulating vascular calcification inhibitor.  
3. Gla domain but not proteolytic activity is required for VSMC calcification inhibition by PT. 
4. PT accumulates at sites of calcification and PT circulation level is reduced in patients with 
vascular calcification. 
5. VSMC exosomes display TF and PS-dependent thrombogenic activity. 
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Table 1. Bovine proteins in human VSMC exosomes detected by mass spectrometry.  
VSMCs were incubated in DMEM supplemented with 0.1% BSA (CTRL, control) and 2.7mM 
Ca/2.5mM P (Ca/P) for 16h and exosomes isolated from cell media by differential centrifugation, 
*proteins with Gla domain.   
Protein  Molecular 
Weight 
Number of 
Assigned 
Spectra 
Number of 
Unique 
Peptides 
Percent 
Coverage 
CTRL Ca/P CTRL Ca/P CTRL Ca/P 
Calcification inhibitors 
a-2-HS-glycoprotein   38 383 469 9 11 31 31 
Transport Proteins 
Serum albumin   69 2834 2824 46 46 65 66 
Matrix proteins 
Fibronectin   272 372 362 26 24 14 12 
Coagulation proteins 
Prothrombin*   71 14 19 4 4 7.5 6.9 
Factor X*   55  4 16 3 1 9.3 2.4 
Factor V   249 10 12 4 3 1.9 1.5 
Factor IX*   47 0 4 0 2 0 7.5 
Protein C*   51 9 6 1 2 2.4 4.2 
Protein S*   75 0 9 0 4 0 5.2 
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Table 2. Characterization of a patient cohort with chronic kidney disease (CKD), which were 
studied for their plasma concentrations of PT in relation to the presence of vascular calcification 
at the iliac/femoral arteries detected by plain X-ray of the pelvis. 
 
 All With vascular 
calcification 
Without vascular 
calcification 
Number 81 44 37 
Gender 
(male/female) 
40/41 25/19 15/22 
Age (years) 55.38±9.33 56.43±9.46 54.14±9.15 
BMI (kg/m2) 23.47±3.40 23.32±3.03 23.66±3.82 
Arterial 
hypertension 
68 (84%) 35 (80%) 33 (89%) 
Smoking 25 (31%) 17 (39%) 8 (22%) 
Diabetes mellitus 7 (9%) 6 (14%) 1 (3%) 
Years on dialysis 8.72±4.40 9.59±4.17 7.68±4.49 
Cholesterol (mg/dl) 5.35±1.22 5.13±0.81 5.60±1.55 
Triglycerides (mg/dl) 2.31±1.36 2.18±1.04 2.46±1.67 
PT (%) 88.36±23.31 82.20±23.09 95.70±21.66* 
   *p=0.0086 
(Student’s T-test); 
PT, prothrombin. 
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